BioStem Technologies Announces Fourth Quarter and Full Year 2025 Financial Results Conference Call

BioStem Technologies, Inc., a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative medicine, will release its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. The company will host a conference call and webcast at 4:30 PM ET on that date, featuring an overview of the quarter from CEO Jason Matuszewski and CFO Brandon Poe. This event is significant for investors and stakeholders as it provides direct access to management's perspective on financial performance and strategic direction in the competitive regenerative medicine market.

The conference call details include a North America toll-free number at (800) 715-9871 and an international toll number at +1 (646) 307-1963, with conference ID 9695874. The webcast will be accessible via https://events.q4inc.com/attendee/218077167, allowing global participation. This transparency in financial reporting underscores BioStem Technologies' commitment to investor relations and regulatory compliance, which is crucial for maintaining trust in the medical technology sector where ethical standards and financial stability are paramount.

BioStem Technologies specializes in harnessing the natural properties of perinatal tissue through its proprietary BioRetain® processing method, which maintains growth factors and preserves tissue structure. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks, ensuring compliance with current Good Tissue Practices and current Good Manufacturing Processes. Its product portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and Neox® and Clarix® product lines, all aimed at advancing regenerative therapies. For more information, visit https://biostemtechnologies.com.

The financial results conference call is important as it offers insights into BioStem Technologies' operational efficiency, revenue growth, and market positioning amid increasing demand for regenerative medicine solutions. Investors will be keen to assess how the company's innovations, like the BioRetain® method, translate into financial performance and competitive advantage. This event also highlights the broader implications for the MedTech industry, where financial health often correlates with research and development capabilities, impacting future product launches and patient outcomes. By providing a platform for direct engagement, BioStem Technologies reinforces its role as a transparent and forward-thinking player in a field that relies heavily on scientific advancement and investor confidence to drive progress in healthcare.